Abstract
Pulmonary hypertension is a rare vascular disease that can affect patients with or surviving malignancy resulting in significant morbidity and high mortality. Malignant diseases can lead to elevated pulmonary artery pressure through different mechanisms, either directly by structural obstruction of pulmonary vessels or indirectly through hypercoagulable state or treatment toxicity culminating in high pulmonary vascular resistance. The most common causes of cancer-related pulmonary hypertension are thromboembolic diseases, tumour emboli and treatment toxicity and less commonly intravascular tumours and malignant extrinsic compression.
| Original language | English |
|---|---|
| Pages (from-to) | 236-242 |
| Number of pages | 7 |
| Journal | Nowotwory |
| Volume | 67 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 29 Dec 2017 |
Bibliographical note
Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- Cancer
- Cardiac toxicity
- Chemotherapy
- Pulmonary arterial hypertension
- Pulmonary hypertension
- Pulmonary veno-occlusive disease